Aardvark Therapeutics, Inc. Common Stock
Market Cap
$116.05M
P/E Ratio
-2.11
EPS
$-2.53
Dividend Yield
0.00%
52-Week Range
$4.74 — $17.94
Volume
287.43K
Avg Volume
283.66K
Beta
3.13
P/E (TTM)
-2.11
Forward P/E
—
PEG Ratio
0.13
P/S (TTM)
0.00
P/B (TTM)
0.93
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.55%
ROA (TTM)
-0.37%
ROIC
—
Gross Margin
0.00%
Operating Margin
0.00%
Net Margin
—
Debt/Equity
0.00
Current Ratio
12.03
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.41%
EPS Growth (5Y)
-0.41%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
$-3.61
EPS Est (Next Year)
$-3.75
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$5.82
Price Target Range
Consensus Target: $31.00(481.6% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
0
Outstanding Shares
21.77M
Float
11.10M
Free Float %
50.99%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2025-02-13
Employees
22
CEO
Tien-Li Lee
Index Membership
—
Website
https://aardvarktherapeutics.com
Aardvark Therapeutics, Inc. Common Stock (AARD) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $116.05M, a P/E ratio of -2.11, AARD is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare AARD against other stocks using dozens of fundamental and technical filters.
Aardvark Therapeutics, Inc. Common Stock (AARD) has a trailing twelve-month (TTM) P/E ratio of -2.11. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Aardvark Therapeutics, Inc. Common Stock (AARD) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Aardvark Therapeutics, Inc. Common Stock (AARD) has a market capitalization of $116.05 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.